✨ Free AI Report
Pyxis Oncology, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Pyxis Oncology, Inc.
Company Research

Pyxis Oncology, Inc.: Business Overview, Financials & Competitive Analysis

Pyxis Oncology, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Analysts rate PYXS as Strong Buy on potential efficacy data and a Pfizer partnership de-risking the program. With a market capitalization up to $300 million, Pyxis is in the micro-cap category. While analysts project a one-year price target of $7.32 with a range of $5.05 to $9.45, the company.

What is Pyxis Oncology, Inc.'s industry? Pyxis Oncology, Inc. (pyxisoncology.com) operates in Biopharmaceutical - Oncology (Antibody-Drug Conjugates & Immuno-Oncology). AskCyborg classifies Pyxis Oncology, Inc. under Biopharmaceutical - Oncology (Antibody-Drug Conjugates & Immuno-Oncology) in its company registry.

Pyxis Oncology is a clinical-stage biotech company developing therapeutics to treat solid tumors, with lead programs including PYX-201 (an antibody-drug conjugate in Phase 1) and PYX-106 (a Siglec-15-targeting immunot...

5/ 10Mixed

Cyborg Score thesis

Analysts rate PYXS as Strong Buy on potential efficacy data and a Pfizer partnership de-risking the...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Oncology (Antibody-Drug Conjugates & Immuno-Oncology)
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Pyxis Oncology, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Pyxis Oncology, Inc.

AskCyborg analysts argue the bull and bear cases for Pyxis Oncology, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Pyxis Oncology, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Pyxis Oncology, Inc. Overview

Pro stress-test →

Pyxis Oncology is a clinical-stage biotech company developing therapeutics to treat solid tumors, with lead programs including PYX-201 (an antibody-drug conjugate in Phase 1) and PYX-106 (a Siglec-15-targeting immunotherapy also in Phase 1). The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Strategic Profile

Pro stress-test →

Pyxis has an in-license agreement with Pfizer to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203. The company is also advancing PYX-107, a CD40 agonist in Phase 2 development for soft tissue sarcomas, esophageal, and pancreatic cancers. The company believes that antibody-drug conjugates and immunotherapies offer unique potential to address difficult-to-treat cancers.

Competitive Landscape

Pro stress-test →

Pyxis competes in the immuno-oncology/ADC space with companies including Vistagen Therapeutics, Janux Therapeutics, BioAtla, Werewolf Therapeutics, and TScan Therapeutics. The ADC segment is crowded but Pyxis differentiates through novel mechanism-of-action (three-pronged MOA for MICVO) and the Pfizer partnership, which provides validation and commercialization support versus pure clinical-stage competitors.

Industry Context

Pyxis Oncology, Inc. operates in Biopharmaceutical - Oncology (Antibody-Drug Conjugates & Immuno-Oncology).

Key facts

Founded: 2018 · Headquarters: Boston, United States · Market cap: $~300M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Pyxis Oncology, Inc..

  • December 2025: Announced positive preliminary Phase 1 data for Micvotabart Pelidotin (MICVO) in recurrent/metastatic head and neck squamous cell carcinoma
  • Strategic partnership with Pfizer for multiple ADC programs reduces development risk and brings commercial infrastructure
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2025Positive preliminary Phase 1 data for Micvotabart Pelidotin (MICVO) in recurrent/metastatic HNSCC
  • November 2025Business update and Q3 2025 financial results reported
  • +1 moreTrack every material event for Pyxis Oncology, Inc. as it happens. Explore monitoring →
Get alerted when Pyxis Oncology, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Janux TherapeuticsT-cell engager immunotherapy platform→BioAtla, Inc.Conditional antibody therapeutic platform→Werewolf TherapeuticsIL-2 and other immuno-oncology biologics→

Compare Pyxis Oncology, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Pyxis Oncology, Inc. operates in Biopharmaceutical - Oncology (Antibody-Drug Conjugates & Immuno-Oncology). See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Oncology (Antibody-Drug Conjugates & Immuno-Oncology) research →
NEW · MCP server

Ask your AI assistant about Pyxis Oncology, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Pyxis Oncology, Inc. and its top competitor on Cyborg Score”
“What did Pyxis Oncology, Inc. do this quarter?”
“Is Pyxis Oncology, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Pyxis Oncology, Inc. do?+
Pyxis Oncology is a clinical-stage biotech company developing therapeutics to treat solid tumors, with lead programs including PYX-201 (an antibody-drug conjugate in Phase 1) and PYX-106 (a Siglec-15-targeting immunot...
What is Pyxis Oncology, Inc.'s Cyborg Score?+
Pyxis Oncology, Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Pyxis Oncology, Inc.'s main competitors?+
Named competitors include Janux Therapeutics, BioAtla, Inc., Werewolf Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Pyxis Oncology, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Pyxis Oncology, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Pyxis Oncology, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical - Oncology (Antibody-Drug Conjugates & Immuno-Oncology) research

Companies in the same sector and named competitors, ranked by Cyborg Score.

4BioAtla, Inc.